Evaluation of naproxen and cromolyn activities against cancer cells viability, proliferation, apoptosis, p53 and gene expression of survivin and caspase-3

References

• Manoukian AS, Woodgett JR. Role of glycogen synthase kinase-3 in cancer: regulation by Wnts and other signaling pathways. Adv Cancer Res 2002;84:203–29
   PubMedGoogle Scholar
• Doble BW, Woodgett JR. GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci 2003;116:1175–86
   PubMed Web of Science ®Google Scholar
• Jope RS, Johnson GVW. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci 2004;29:95–102
   PubMed Web of Science ®Google Scholar
• Liao X, Zhang L, Thrasher JB, et al. Glycogen synthase kinase-3β suppression eliminates tumor necrosis factor-related apoptosis-inducing resistance in prostate cancer. Mol Cancer Ther 2003;2:1215–22
   PubMed Web of Science ®Google Scholar
• Mazor M, Kawano Y, Zhu H, et al. Inhibition of glycogen synthase kinase-3 represses androgen receptor activity and prostate cancer cell growth. Oncogene 2004;23:7882–92
   PubMedGoogle Scholar
• Shakoori A, Ougolkov A, Yu ZW, et al. Deregulated GSK3 beta activity in colorectal cancer: its association with tumor-cell survival and proliferation. Biochem Biophys Res Commun 2005;334:1365–73
   PubMed Web of Science ®Google Scholar
• Wulfkuhle JD, Aquino JA, Calvert VS, et al. Signal pathway profiling of ovarian cancer from human tissue specimens using reverse-phase protein microarrays. Proteomics 2003;3:2085–90
   PubMed Web of Science ®Google Scholar
• Liao X, Thrasher JB, Holzbeierlein J, et al. Glycogen synthase kinase-3 activity is required for androgen-stimulated gene expression in prostate cancer. J Endocrinol 2004;145:2941–9
   Google Scholar
• Leis H, Segrelles C, Ruiz S, et al. Expression, localization, and activity of glycogen synthase kinase 3β during mouse skin tumorigenesis. Mol Carcinog 2002;35:180–5
   Google Scholar
• Ougolkov AV, Fernandez-Zapico ME, Savoy DN, et al. Glycogen synthase kinase-3β participates in nuclear factor κB-mediated gene transcription and cell survival in pancreatic cancer cells. Cancer Res 2005;65:2076–81
   PubMed Web of Science ®Google Scholar
• Hoeflich KP, Luo J, Rubie EA, et al. Requirement for glycogen synthase kinase-3β in cell survival and NF-κB activation. Nature 2000;406:86–90
   PubMed Web of Science ®Google Scholar
• Schwabe RF, Brenner DA. Role of glycogen synthase kinase-3 in TNF-α-induced NF-κB activation and apoptosis in hepatocytes. Am J Physiol Gastrointest Liver Physiol 2002;283:G204–11
   PubMedGoogle Scholar
• Demarchi F, Bertoli C, Sandy P, Schneider C. Glycogen synthase kinase-3β regulates NF-κB1/p105 stability. J Biol Chem 2003;278:39583–90
   PubMed Web of Science ®Google Scholar
• Schwabe RF, Brenner DA. Role of glycogen synthase kinase-3 in TNF-α-induced NF-κB activation and apoptosis in hepatocytes. Am J Physiol 2002;283:G204–11
   PubMedGoogle Scholar
• Kulikov R, Boehme KA, Blattner C. Glycogen synthase kinase 3-dependent phosphorylation of Mdm2 regulates p53 abundance. Mol Cell Biol 2005;25:7170–80
   PubMedGoogle Scholar
• Lichtenberger LM, Romero JJ, Dial EJ, Moore JE. Naproxen-PC: a GI safe and highly effective anti-inflammatory. Inflammopharmacology 2009;17:1–5
   Google Scholar
• Foreman JC, Haliett MB, Mongar JL. Site of action of the anti-allergic drugs cromoglycate and doxantrazole. Br J Pharmacol 1981;11:473P–4P
   Google Scholar
• Storms W, Kaliner MA. Cromolyn sodium: fitting an old friend into current asthma treatment. J Asthma 2005;42:79–89
   PubMed Web of Science ®Google Scholar
• Ribeiro G, Benadiba M, Colquhoun A, de Oliveira Silva D. Diruthenium (II, III) complexes of ibuprofen, aspirin, naproxen and indomethacin non-steroidal anti-inflammatory drugs: synthesis, characterization and their effects on tumor-cell proliferation. Polyhedron 2008;27:1131–7
   Web of Science ®Google Scholar
• Van de Loosdrecht AA, Beelen RH, Ossenkoppele GJ, et al. A tetrazolium based colorimetric MTT assay to quantitate human monocyte mediated cytotoxicity against leukemic cells from cell lines and patients with acute myeloid leukemia. J Immunol Methods 1994;174:311–20
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCt method. Methods 2001;25:402–8
   PubMed Web of Science ®Google Scholar
• Bates S, Vousden KH. Mechanisms of p53-mediated apoptosis. Cell Mol Life Sci 1999;55:28–37
   PubMed Web of Science ®Google Scholar
• Bennett M, Macdonald K, Chan SW, et al. Cell surface trafficking of Fas: a rapid mechanism of p53 mediated apoptosis. Science 1998;282:290–3
   PubMed Web of Science ®Google Scholar
• Asanuma K, Kobayashi D, Furuya D, et al. A role for survivin in radio resistance of pancreatic cancer cells. Jpn J Cancer Res 2002;93:1057–62
   PubMedGoogle Scholar
• Sarela AI, Verbeke CS, Ramsdale J, et al. Expression of survivin, a novel inhibitor of apoptosis and cell cycle regulatory protein, in pancreatic adenocarcinoma. Br J Cancer 2002;86:886–92
   PubMed Web of Science ®Google Scholar
• Altieri DC. The molecular basis and potential role of surviving in cancer diagnosis and therapy. Trends Mol Med 2001;7:542–7
   PubMed Web of Science ®Google Scholar
• Lavrik IN, Golks A, Krammer PH. Caspases: pharmacological manipulation of cell death. J Clin Invest 2005;115:2665–72
   PubMed Web of Science ®Google Scholar
• Blanc C, Deveraux QL, Krajewski S, et al. Caspase-3 is essential for procaspase-9 processing and cisplatin-induced apoptosis of MCF-7 breast cancer cells. Cancer Res 2000;60:4386–90
   PubMed Web of Science ®Google Scholar
• Yang X-H, Sladek TL, Liu X, et al. Reconstitution of caspase 3 sensitizes MCF-7 breast cancer cells to doxorubicin- and etoposide-induced apoptosis. Cancer Res 2001;61:348–54
   PubMed Web of Science ®Google Scholar
• Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature 2001;411:342–8
   PubMed Web of Science ®Google Scholar
• Srinivas S, Feldman D. A phase II trial of calcitriol and naproxen in recurrent prostate cancer. Anticancer Res 2009;29:3605–10
   PubMed Web of Science ®Google Scholar
• Hussain T, Gupta S, Mukhtar H. Cyclooxygenase-2 and prostate carcinogenesis. Cancer Lett 2003;191:125–35
   PubMed Web of Science ®Google Scholar
• De Marzo AM, Nakai Y, Nelson WG. Inflammation, atrophy and prostate carcinogenesis. Urol Oncol 2007;25:398–400
   PubMed Web of Science ®Google Scholar
• Cohen BL, Gomez P, Omori Y, et al. Cyclooxygenase-2 (COX-2) expression is an independent predictor of prostate cancer recurrence. Int J Cancer 2006;119:1082–7
   PubMed Web of Science ®Google Scholar
• Thiel A, Heinonen M, Rintahaka J, et al. Expression of cyclooxygenase-2 is regulated by glycogen synthase kinase-3β in gastric cancer cells. J Biol Chem 2006;281:4564–9
   Google Scholar
• Yona D, Arber JN. Coxibs and cancer prevention. J Cardiovasc Pharmacol 2006;47:S76–81
   Google Scholar
• Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002;94:252–66
   PubMed Web of Science ®Google Scholar
• Ribatti D, Crivellat E, Roccaro AM, et al. Mast cell contribution to angiogenesis related to tumour progression. Clin Exp Allergy 2004;34:1660–4
   PubMed Web of Science ®Google Scholar
• Chichlowski M, Westwood GS, Abraham SN, Hale LP. Role of mast cells in inflammatory bowel disease and inflammation-associated colorectal neoplasia in IL-10-deficient mice. PLoS One 2010;5:e12220–8
   Google Scholar
• Arumugam T, Ramachandran V, Logsdon CD. Effect of cromolyn on S100P interactions with RAGE and pancreatic cancer growth and invasion in mouse models. J Natl Cancer Inst 2006;98:1806–18
   PubMed Web of Science ®Google Scholar
• Arumugam T, Simeone DM, Schmidt AM, Logsdon CD. S100P stimulates cell proliferation and survival via receptor for activated glycation end products (RAGE). J Biol Chem 2004;279:5059–65
   PubMed Web of Science ®Google Scholar